VIVANI MEDICAL INC (VANI) Stock Price & Overview

NASDAQ:VANI • US92854B1098

Current stock price

1.42 USD
+0.04 (+2.9%)
Last:

The current stock price of VANI is 1.42 USD. Today VANI is up by 2.9%. In the past month the price increased by 16.95%. In the past year, price increased by 31.43%.

VANI Key Statistics

52-Week Range0.9228 - 1.92
Current VANI stock price positioned within its 52-week range.
1-Month Range0.9228 - 1.53
Current VANI stock price positioned within its 1-month range.
Market Cap
120.203M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.43
Dividend Yield
N/A

VANI Stock Performance

Today
+2.9%
1 Week
+28.97%
1 Month
+16.95%
3 Months
-6.76%
Longer-term
6 Months -14.81%
1 Year +31.43%
2 Years -14.81%
3 Years +24.32%
5 Years N/A
10 Years N/A

VANI Stock Chart

VIVANI MEDICAL INC / VANI Daily stock chart

VANI Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to VANI. When comparing the yearly performance of all stocks, VANI turns out to be only a medium performer in the overall market: it outperformed 62.92% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VANI Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to VANI. VANI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VANI Earnings

Next Earnings DateMay 11, 2026
Last Earnings DateMar 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.09
Revenue Reported
EPS Surprise 11.76%
Revenue Surprise %

VANI Forecast & Estimates

9 analysts have analysed VANI and the average price target is 5.36 USD. This implies a price increase of 277.11% is expected in the next year compared to the current price of 1.42.


Analysts
Analysts82.22
Price Target5.36 (277.46%)
EPS Next Y22.91%
Revenue Next YearN/A

VANI Groups

Sector & Classification

VANI Financial Highlights

Over the last trailing twelve months VANI reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 2.27% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-26.61M
Industry RankSector Rank
PM (TTM) N/A
ROA -67.55%
ROE -169.16%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%18.18%
Sales Q2Q%N/A
EPS 1Y (TTM)2.27%
Revenue 1Y (TTM)N/A

VANI Ownership

Ownership
Inst Owners6.45%
Shares84.65M
Float55.58M
Ins Owners34.31%
Short Float %0.96%
Short Ratio2.21

About VANI

Company Profile

VANI logo image Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.

Company Info

IPO: 2014-12-05

VIVANI MEDICAL INC

1350 S. Loop Road

Alameda CALIFORNIA US

Employees: 42

VANI Company Website

VANI Investor Relations

Phone: 18887057274

VIVANI MEDICAL INC / VANI FAQ

Can you describe the business of VIVANI MEDICAL INC?

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.


What is the current price of VANI stock?

The current stock price of VANI is 1.42 USD. The price increased by 2.9% in the last trading session.


Does VIVANI MEDICAL INC pay dividends?

VANI does not pay a dividend.


What is the ChartMill rating of VIVANI MEDICAL INC stock?

VANI has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is VANI stock listed?

VANI stock is listed on the Nasdaq exchange.


Should I buy VANI stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VANI.


Can you provide the number of employees for VIVANI MEDICAL INC?

VIVANI MEDICAL INC (VANI) currently has 42 employees.